Celixir Heartcel - Immunomodulatory Progenitor Cells
From Pipeline
PHASE 2 : Our first investigational cardiac regenerative medicine consists of iMP cells. iMP cells are designed to treat patients with ischaemic heart disease – ischaemic cardiomyopathy – undergoing coronary artery bypass graft (CABG). They are injected around cardiac scar tissue via a single application during bypass surgery.
STATUS:
STATUS:
We have successfully completed European Phase 2 trials using iMP cells as a cardiac-specific cellular medicine. Additional trials are set to begin in 2018. iMP cells have been designated as an advanced therapeutic medicinal product by the European Medicines Agency. A Phase 2 trial in Kawasaki disease is also planned.
Customer reviews
No reviews were found for Celixir Heartcel - Immunomodulatory Progenitor Cells. Be the first to review!